Lilly Launches Second Phase 3 Trial of Orforglipron for Obesity Indication in China, Enrolling Patients with Type 2 Diabetes and Overweight/Obesity

On September 6, the official website of the Drug Clinical Trial Information Publicity and Registration Platform showed that Eli Lilly and Company registered a Phase III clinical trial (study code: ATTAIN-2) for the oral small-molecule GLP-1R agonist Orforglipron (LY3502970) in treating patients with Type 2 diabetes who are obese or overweight.

ATTAIN-2 is a randomized, double-blind, placebo-controlled global Phase III study designed to evaluate the efficacy and safety of once-daily oral Orforglipron in adult subjects with type 2 diabetes who are obese or overweight. The study aims to enroll 1,500 adult subjects with type 2 diabetes (HbA1c: 7%-10%) and a body mass index (BMI) ≥27 kg/m², who have experienced at least one failed dietary weight loss attempt.According to the public information, this study plans to enroll 110 Chinese patients.

Previously, on August 11, Eli Lilly registered the first Phase III clinical trial (study code: ATTAIN-1) of Orforglipron for the treatment of obesity or overweight patients with weight-related comorbidities on the Drug Clinical Trial Information Publicity and Registration Platform.

Eli Lilly and Company is currently fully advancing the clinical development of Orforglipron, having initiated multiple Phase III clinical trials of Orforglipron to further investigate its efficacy and safety in treating obesity and overweight (ATTAIN series studies) as well as type 2 diabetes (ACHIEVE series studies).

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reproduce it, please leave a message or send a notification to the WeChat Official Account backend, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.